BioPharmSignal logoBioPharmSignal

Biotech News

PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen (PEPG)PepGenEarnings

– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients enrolled and having received at least one dose – – Recent $115 million financing extends cash runway

Related news

PEPGPepGen2026-08-06 11:32 EST

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PEPGPepGen2026-05-12 20:05 EST

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

View all latest news

PepGen

Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle. PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression. FREEDOM2 The FREEDOM2...

Recent company news

PEPGPepGen2026-08-06 11:32 EST

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PEPGPepGen2026-08-06 11:30 EST

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

PEPGPepGen2026-05-21 11:00 EST

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

PEPGPepGen2026-05-12 20:05 EST

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

PEPGPepGen2026-03-30 20:05 EST

PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

Stock data

Close
3.14 USD
Market cap
100.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States